Výsledky vyhledávání - "Kate J Whitaker"

Data from Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy

Autor: Toby A. Eyre, John N. Allan, Bruce D. Cheson, Kayla Bigelow, Colleen Dorsey, Andrew D. Zelenetz, Amber C. King, Julie M. Goodfriend, Chadi Nabhan, Hanna B. Weissbrot, Jason C. Lee, Neil Bailey, Erica B. Bhavsar, Talha Munir, Nicolas Martinez-Calle, Christopher P. Fox, Thomas D. Rodgers, Stephen J. Schuster, Timothy J. Voorhees, Kentson Lam, Rachael Pocock, Othman S. Akhtar, Pratik Shah, Krista M. Isaac, Ariel F. Grajales-Cruz, Sirin Khajavian, Andrea Sitlinger, Allison M. Winter, Kate J. Whitaker, Christine A. Garcia, Helen Parry, Craig A. Portell, Paul M. Barr, Joanna Rhodes, Catherine C. Coombs, Michael Choi, Bita Fakhri, Satyen Gohil, John M. Pagel, Jeffrey J. Pu, Pallawi Torka, Alan P. Skarbnik, Jacqueline Barrientos, Javier A. Pinilla-Ibarz, Guilherme Fleury Perini, Maryam Sarraf Yazdy, Chaitra S. Ujjani, Mazyar Shadman, Danielle Brander, Nicole Lamanna, Brian T. Hill, Ryan Jacobs, Lindsey E. Roeker, Anthony R. Mato

Purpose:Venetoclax-based therapy is a standard-of-care option in first-line and relapsed/refractory chronic lymphocytic leukemia (CLL). Patient management following venetoclax discontinuation remains nonstandard and poorly understood.Experimental Des

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e72e05cfed97bbc9e2e47db93b397aae
https://doi.org/10.1158/1078-0432.c.6528851

Zobrazit plný text záznamu

Supplemental Figure 2 from Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy

Supplemental Figure 2: Progression free survival of patients without prior BTKi exposure who had progressed on venetoclax and were then treated with BTKi.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::391825ca38ac12df33b7f05e19ba469f
https://doi.org/10.1158/1078-0432.22474643.v1

Zobrazit plný text záznamu

Supplemental Figure 1 from Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy

Supplemental Figure 1: Overall survival of entire cohort from initiation of venetoclax.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48f28a1d557f9e1d57cd60895ef876dc
https://doi.org/10.1158/1078-0432.22474646.v1

Zobrazit plný text záznamu

Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy

Autor: Neil Bailey, Erica B. Bhavsar, Danielle M. Brander, Ryan Jacobs, Amber C. King, Satyen H. Gohil, Chadi Nabhan, Maryam Sarraf Yazdy, Chaitra S. Ujjani, Pratik Shah, Bruce D. Cheson, Catherine C. Coombs, Hanna Weissbrot, Jacqueline C. Barrientos, John M. Pagel, Michael Y. Choi, Thomas D. Rodgers, Andrea Sitlinger, Rachael Pocock, Nicolas Martinez-Calle, Craig A. Portell, Lindsey E. Roeker, Andrew D. Zelenetz, Allison M. Winter, Colleen Dorsey, Javier Pinilla-Ibarz, Paul M. Barr, Othman S. Akhtar, Kate J Whitaker, Guilherme Fleury Perini, Jason C. Lee, Christine A. Garcia, Jeffrey J. Pu, Pallawi Torka, Timothy J Voorhees, Bita Fakhri, Mazyar Shadman, Ariel F Grajales-Cruz, Toby A. Eyre, Julie Goodfriend, John N. Allan, Joanna Rhodes, Kayla Bigelow, Helen Parry, Nicole Lamanna, Anthony R. Mato, Krista Isaac, Sirin Khajavian, Christopher P. Fox, Stephen J. Schuster, Kentson Lam, Talha Munir, Brian T. Hill, Alan P Skarbnik

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research, vol 26, iss 14

Purpose: Venetoclax-based therapy is a standard-of-care option in first-line and relapsed/refractory chronic lymphocytic leukemia (CLL). Patient management following venetoclax discontinuation remains nonstandard and poorly understood. Experimental D

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b4ec23eccb2df4bc0876922b8d9c701
https://pubmed.ncbi.nlm.nih.gov/32366672

Zobrazit plný text záznamu

Veneto-STOP Study: Sequential Assessment of Minimal Residual Disease By Next Generation Sequencing to Optimize Outcomes and Minimize Exposure in Venetoclax-Treated CLL Patients

Autor: Chaitra S. Ujjani, Allison P. Jacob, Mark B. Geyer, Kate J Whitaker, Mazyar Shadman, Lindsey E. Roeker, Andrew D. Zelenetz, Colleen Dorsey, Anthony R. Mato

Publikováno v: Blood. 134:1758-1758

Background: The treatment indications for venetoclax in CLL are broadening quickly. While the initial approval was for relapsed patients with del 17p (Stilgenbauer S, et al. JCO 2018), it has subsequently been extended to all patients (Seymour J, et

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b59b9c67dd2d2126833a37d9405fb4ae
https://doi.org/10.1182/blood-2019-124002

Zobrazit plný text záznamu

Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies

Autor: Amber C. King, Michael Y. Choi, Guilherme Fleury Perini, Sirin Khajavian, Mazyar Shadman, Kentson Lam, Jason C. Lee, Bita Fakhri, Jeffrey J. Pu, Danielle M. Brander, Pratik Shah, Colleen Dorsey, Bruce D. Cheson, Kayla Bigelow, Talha Munir, Neil Bailey, Ryan Jacobs, Stephen J. Schuster, Thomas D. Rodgers, Hanna Weissbrot, Satyen H. Gohil, Lindsey E. Roeker, Andrew D. Zelenetz, Andrea Sitlinger, Pallawi Torka, Kate J Whitaker, Chaitra S. Ujjani, Nicolas Martinez-Calle, Christopher P. Fox, Brian T. Hill, Alan P Skarbnik, Paul M. Barr, Chadi Nabhan, Javier Pinilla Ibarz, Anthony R. Mato, Krista Isaac, Christine A. Garcia, Ariel F Grajales-Cruz, Allison M. Winter, Maryam Sarraf Yazdy, Toby A. Eyre, John M. Pagel, Jacqueline C. Barrientos, John N. Allan, Erica B. Bhavsar, Othman S. Akhtar, Julie Goodfriend, Helen Parry, Nicole Lamanna, Craig A. Portell, Timothy J Voorhees, Catherine C. Coombs, Rachael Pocock, Joanna Rhodes

Publikováno v: Blood. 134:502-502

Introduction: Venetoclax (VEN) based therapy has become a standard of care in front line and relapsed-refractory (R/R) CLL based on favorable efficacy and toxicity. Whereas prospective data regarding activity of therapies following ibrutinib (IBR) or

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::931e807f711f64fe625d8835d32c0fa4
https://doi.org/10.1182/blood-2019-123747

Zobrazit plný text záznamu

Toxicities and Outcomes of Acalabrutinib-Treated Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis of Real World Patients

Publikováno v: Blood. 134:4311-4311

Introduction: Acalabrutinib (acala) is an irreversible, second generation Bruton tyrosine kinase inhibitor (BTKi) approved by the FDA for the treatment of relapsed/refractory (R/R) mantle cell lymphoma, and is in advanced stages of clinical testing f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7cbdfaf68222e7aad72bee67caa233ef
https://doi.org/10.1182/blood-2019-130062

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání